American Association for the Study of Liver Diseases

Post hoc phase 2b analyses suggest peogzafermin may benefit severe fibrosis regardless of MASH patients' cirrhosis status.

We sat down with Jessica Ferrell, PhD, to discuss key takeaways from her session about the developing role of bile acids both for and beyond cholestatic and metabolic diseases.

Retatrutide, an investigational triple-agonist therapy, may help resolve liver fat prior to progression to severe disease.

Results from this prospective study in Japan found older age, history of hepatocellular carcinoma, and decreased albumin level at SVR were significantly associated with liver-related mortality after SVR.

We sat down with Ana Lleo, MD, PhD, to discuss primary sclerosing cholangitis biomarkers and the need for future research in this field.

New pooled phase 3 and extension trial data show odevixibat continues to improve disease management and itch reduction in children with Alagille syndrome.

Results presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases highlighted an association between food insecurity and low household income with the risk of NAFLD in adolescents.

Investigators observe significantly greater 15-year survival rates after bariatric surgery among patients who achieve MASH resolution versus those who do not.

Phase 3 data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases demonstrated the safety and efficacy of seladelpar in patients with primary biliary cholangitis through 12 months of treatment.

Interim data presented at The Liver Meeting highlight the novel antigen-specific immunotherapy's potential in resolving hepatitis B.

Madhumita Premkumar, MD, discusses a nationwide, cost-efficient eradication strategy she believes could benefit Americans' efforts to curb HCV.

Tatyana Kushner, MD, MSCE, sat down with HCPLive to discuss the White House hepatitis C elimination plan.

New analyses from the phase 3 MAESTRO-NASH support the oral daily drug's benefit for cardiovascular and hormonal outcomes over 1 year.

We sat down with Mark Sundrud, PhD, to discuss bile acids and T cells in cholestatic liver disease and the future of research regarding the interplay between intestinal and liver functions.

Findings from The Liver Meeting show the impact of acute alcoholic hepatitis on progression to severe disease and risk of death among younger populations.

Data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases (AASLD) showed similar assisted reproductive technology outcomes for patients with and without chronic liver disease.

As more cases continue to disproportionately affect US women, an expert explains the biologic, sociocultural and clinical factors impacting the climb.

A trio of investigators discuss how research into bile acid interplay with the gut may lead to breakthroughs in treating conditions like NAFLD and NASH.

The founder of PSC Partners Seeking a Cure discusses how screening and treatment for the rare disease has evolved since her diagnosis 20 years ago.

A trio of scientists discuss the inception of a daylong Liver Meeting symposium around a little-understood subject in hepatic disease.